- Home
- IMNM vs ELMD Comparison
IMNM vs ELMD Comparison
Compare IMNM & ELMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNM
- ELMD
- Stock Information
- Founded
- IMNM 2006
- ELMD 1992
- Country
- IMNM United States
- ELMD United States
- Employees
- IMNM N/A
- ELMD N/A
- Industry
- IMNM Medicinal Chemicals and Botanical Products
- ELMD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- IMNM Health Care
- ELMD Health Care
- Exchange
- IMNM Nasdaq
- ELMD Nasdaq
- Market Cap
- IMNM 747.7M
- ELMD N/A
- IPO Year
- IMNM 2020
- ELMD 2010
- Fundamental
- Price
- IMNM $10.97
- ELMD $27.73
- Analyst Decision
- IMNM Strong Buy
- ELMD
- Analyst Count
- IMNM 5
- ELMD 0
- Target Price
- IMNM $28.60
- ELMD N/A
- AVG Volume (30 Days)
- IMNM 874.7K
- ELMD 92.7K
- Earning Date
- IMNM 11-13-2024
- ELMD 02-11-2025
- Dividend Yield
- IMNM N/A
- ELMD N/A
- EPS Growth
- IMNM N/A
- ELMD 94.54
- EPS
- IMNM N/A
- ELMD 0.72
- Revenue
- IMNM $10,129,000.00
- ELMD $57,060,000.00
- Revenue This Year
- IMNM N/A
- ELMD $14.27
- Revenue Next Year
- IMNM N/A
- ELMD N/A
- P/E Ratio
- IMNM N/A
- ELMD $38.26
- Revenue Growth
- IMNM N/A
- ELMD 14.73
- 52 Week Low
- IMNM $8.33
- ELMD $9.81
- 52 Week High
- IMNM $30.96
- ELMD $31.31
- Technical
- Relative Strength Index (RSI)
- IMNM 39.61
- ELMD 48.70
- Support Level
- IMNM $10.76
- ELMD $26.91
- Resistance Level
- IMNM $15.13
- ELMD $28.98
- Average True Range (ATR)
- IMNM 0.98
- ELMD 1.22
- MACD
- IMNM -0.29
- ELMD -0.45
- Stochastic Oscillator
- IMNM 4.81
- ELMD 21.93
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.